- The Withings ScanWatch has received FDA clearance for atrial fibrillation detection through ECG.
- The FDA also granted clearance to the device for measuring users’ SpO2 levels.
- Shoppers will be able to grab a ScanWatch as soon as early November for $279.
The Withings ScanWatch is now the first wearable to earn FDA clearance for atrial fibrillation detection and SpO2 measurement from the wrist. This feat makes it the most medically advanced hybrid smartwatch on the market. While the device and its ECG monitor have previously received CE medical certification in Europe, the company was eager to face the thorough scrutiny of the FDA and is now excited to bring the watch to North American markets next month.
Read further: Withings ScanWatch review
Withings ScanWatch ECG and blood oxygen monitoring
The Withings ScanWatch features a built-in medical-grade electrocardiogram (ECG) that allows users to see real-time results on their paired smartphones. Now with FDA approval, the ScanWatch can officially detect if a user has atrial fibrillation (AFib). It can also alert individuals to a potential heart event. Plus, all ECG readings are stored in the Withings Health Mate app for users to review or share with a doctor.
In addition to a medical-grade ECG, the Withings ScanWatch also now boasts FDA clearance of its SpO2 functionality. Users can monitor blood oxygen levels as well as use their ScanWatch to detect issues from respiratory disorders. SpO2 monitoring can even alert individuals to nighttime breathing disturbances, an indicator of sleep apnea. It is another powerful health monitoring tool flooding the wearables market and an attractive feature of the Withings hybrid smartwatch.
Together, these two approvals make the Withings ScanWatch a wearable worth noting as it makes its way to US shores. With a plethora of additional health and fitness features, the device offers much more than the average hybrid smartwatch.
Withings ScanWatch US availability
Joining the ranks of devices like the Samsung Galaxy Watch 4 and Apple Watch Series 6 with FDA-approved ECG sensors, the Withings Scanwatch can finally launch in the United States. The company has been waiting to bring the device to US consumers since its announcement in January 2020. Shoppers can expect to find the ScanWatch on sale early this November on the Withings site as well as on Amazon and at Best Buy. To start, the watches will be priced at $279 for the 38mm model and $299 for the 42mm model.